Therapies from Fucoidan: New Developments

Fitton, J. Helen; Stringer, Damien N.; Park, Ah Young; Karpiniec, Samuel S.

doi:10.3390/md17100571

Cited by 128 publications

(97 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fucoidans are a group of high molecular weight, fucose-based polysaccharides recognized as a key component of particular brown macroalgae species [4]. The bioactive properties of fucoidan preparations have been assessed in a range of in vitro and animal models [5] and include demonstrated antimicrobial [6], antiviral [7] and anticancer [8] effects. While evidence from animal models suggests fucoidans may also possess immune-modulating effects [9,10], the ability of fucoidans to act as potential modulators of mucosal health generally, and mucosal immune function appears underappreciated and requires further investigation given (i) the fucose-based structure of fucoidans, (ii) the role of fucose as a terminal sugar in human mucin glycoproteins [11], and (iii) evidence from ex vivo tissue preparations suggesting fucose may regulate gut motility [12].…”

Section: Introductionmentioning

confidence: 99%

Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study

et al. 2020

View full text Add to dashboard Cite

Nutritional strategies to help promote immune competence are of particular interest for a range of population groups. This study aimed to assess the potential impacts of fucoidan, a seaweed-derived bioactive polysaccharide, on gut markers of immunity and inflammation. A group of professional team-sport athletes were selected for inclusion in the study given the recognized potential for intense physical activity to induce alterations in immune function. A retrospective analysis was performed on stored fecal samples which had been collected from professional team-sport athletes (n = 22) and healthy adults (n = 11) before and after seven days of supplementation with fucoidan (Fucus vesiculosus/Undaria pinnatifida extract, 1 g/d). Fecal concentrations of calprotectin, secretory immunoglobulin A (sIgA) and lysozyme were determined using enzyme-linked immunosorbent assays. The supplement was well tolerated by participants with no adverse events reported. At baseline, fecal lysozyme concentrations were ~73% higher in the healthy adults compared to the professional athletes (p = 0.001). For the professional athletes, a significant (~45%) increase in fecal lysozyme was observed following the supplementation period (p = 0.001). These data suggest that fucoidan supplementation may have the potential to promote the secretion of antimicrobial peptides in specific population groups and contribute to the regulation of mucosal immune health.

show abstract

Section: Introductionmentioning

confidence: 99%

Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…An attractive array of biological activities of fucoidan has been reported for its immune modulation, inhibition of tumor cells, blood lipid-reduction, treatment of age-related macular degeneration, antioxidant activity, antimicrobial properties, anti-viral vaccine adjuvant, etc. [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

“…Thus, fucoidan has been used in transdermal formulations targeting inflammatory skin conditions, for treatment of superficial thrombosis, vascular permeability diseases, subcutaneous wounds, and burns [1]. The use of anticoagulants is one of the options for the treatment of disseminated intravascular coagulation and venous thromboembolic disease [16].…”

Section: Introductionmentioning

confidence: 99%

The Pharmacokinetics of Fucoidan after Topical Application to Rats

et al. 2019

View full text Add to dashboard Cite

Fucoidan, a fucose-rich polysaccharide from brown algae, has been used for transdermal formulations targeting inflammatory skin conditions, for the treatment of thrombosis, vascular permeability diseases, subcutaneous wounds, and burns. However, the pharmacokinetics of fucoidan after topical application has not been described. In this study, an ointment (OF) containing 15% fucoidan was topically applied to rats at the doses of 50–150 mg/g. The anti-Xa activity was selected as the biomarker, and the amidolytic assay method was validated and applied for pharmacokinetic studies of fucoidan. Fucoidan in OF penetrated the skin and distributed into the skin, striated muscle, and plasma with AUC0–48 = 0.94 μg·h/g, 2.22 μg·h/g, and 1.92 µg·h/mL, respectively. The longest half-life for fucoidan was observed in plasma, then in striated muscle and skin. It was found that the pharmacokinetics of fucoidan after topical OF application was linear, in the range of 50–150 mg/kg. No accumulation of fucoidan in plasma was observed after repeated topical applications of 100 mg/kg during five days. Our results support the rationality of topical application of formulations with fucoidan.

show abstract

“…Las algas y macroalgas, han ganado gran interés en las últimas décadas, debido a sus propiedades inmunomoduladoras, anticancerígenas, antidiabéticas, antioxidantes y antivirales 26,101 . Los fucoidanos son uno de los principales polisacaráridos producidos por algas pardas como el cochayuyo (Durvillaea antarctica).…”

Section: Fuentes De Opnd Prebióticos Y Suunclassified